Shares of Indivior PLC (LON:INDV) have earned a consensus recommendation of “Buy” from the seven ratings firms that are currently covering the firm, reports. One research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is GBX 472.43 ($6.36).

INDV has been the subject of a number of recent analyst reports. Numis Securities reaffirmed a “buy” rating and set a GBX 500 ($6.73) target price on shares of Indivior in a report on Friday, October 20th. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 400 ($5.38) target price on shares of Indivior in a report on Friday, September 15th. Jefferies Group reduced their target price on Indivior from GBX 540 ($7.27) to GBX 358 ($4.82) and set a “buy” rating for the company in a report on Friday, September 8th. Citigroup raised Indivior to a “buy” rating and lifted their target price for the company from GBX 280 ($3.77) to GBX 490 ($6.59) in a report on Wednesday, November 8th. Finally, Morgan Stanley lifted their target price on Indivior from GBX 320 ($4.31) to GBX 410 ($5.52) and gave the company an “equal weight” rating in a report on Thursday, November 9th.

Shares of Indivior (LON INDV) traded up GBX 1.61 ($0.02) during trading on Thursday, reaching GBX 365.49 ($4.92). The company had a trading volume of 1,988,081 shares, compared to its average volume of 3,150,000. Indivior has a fifty-two week low of GBX 246.50 ($3.32) and a fifty-two week high of GBX 421.50 ($5.67).

ILLEGAL ACTIVITY WARNING: This article was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another site, it was illegally copied and reposted in violation of US & international trademark & copyright law. The correct version of this article can be viewed at

Indivior Company Profile

Indivior PLC (Indivior) is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence (the Indivior Business). Its treatment and pipeline focus is opioid use disorder, alcohol use disorder, overdose rescue and central nervous system (CNS) disorders/schizophrenia.

Analyst Recommendations for Indivior (LON:INDV)

Receive News & Ratings for Indivior PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.